Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

NCT01768117 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
13
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer